A putative class action has been lodged in New Jersey against the Princeton-based maker of the cholesterol-reducing drug Atorvastatin, which was found to be tainted with glass particles.
The suit was filed on Nov. 29, the day after Ranbaxy Pharmaceuticals announced that it had recalled several lots of the drug and the day before the Food & Drug Administration issued a public advisory.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
